Physician specialty
Medical Oncology
At a glance
- Practicing in the U.S.
- 5,662
- Per 100,000 residents
- 1.7
- Women
- 36%
- Median years since graduating
- 24
Training path
- College (bachelor’s degree) 4 years
- Medical school (MD or DO) 4 years
- Internal medicine residency 3 years
- Medical oncology fellowship (often combined with hematology) 2–3 years
Training after medical school: 5–6 years. From the start of college: about 13–14 years.
Usual minimum program lengths from ACGME program requirements. Some doctors take extra research years or a second fellowship.
Who they are
- MD (DOs make up the rest) 96%
- Women 36%
- Graduated 35 or more years ago 23%
- Offer telehealth 65%
- Accept Medicare’s approved amount 96%
Sex and credentials from NPPES. Graduation year, telehealth and Medicare assignment from Medicare Care Compare, which covers clinicians enrolled in Medicare.
Where they practice
What they do most for Medicare patients
- Established patient office or other outpatient visit, 30-39 minutes 1,100,544
- Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count 929,139
- Insertion of needle into vein for collection of blood sample 830,297
- Established patient office or other outpatient visit, 40-54 minutes 466,774
- Established patient office or other outpatient visit, 20-29 minutes 402,957
- Injection of drug or substance under skin or into muscle 313,294
- Administration of chemotherapy into vein, 1 hour or less 286,926
- Injection of additional new drug or substance into vein 273,879
- Blood test, comprehensive group of blood chemicals 269,529
- Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less 197,225
- Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 142,444
- Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes 118,858
Services billed to traditional Medicare in 2023 (Physician and Other Practitioners data); drugs given in the office are left out.
What they prescribe most
- Anastrozole (Arimidex) 9.3%
- Letrozole (Femara) 5.7%
- Prednisone (Rayos) 4.9%
- Apixaban (Eliquis) 4.5%
- Dexamethasone (Hemady, Maxidex, Ozurdex) 3.6%
- Prochlorperazine Maleate 3.4%
- Ondansetron Hcl 3.3%
- Abiraterone Acetate (Zytiga) 2.8%
- Lenalidomide (Revlimid) 2.7%
- Acyclovir (Zovirax) 2.6%
- Gabapentin (Gralise, Neurontin) 2.4%
- Hydroxyurea (Siklos, Droxia, Hydrea) 2.4%
- Oxycodone Hcl (Oxycontin, Roxicodone, Roxybond) 2.3%
- Tamoxifen Citrate (Soltamox) 2.2%
- Levothyroxine Sodium (Euthyrox, Levo-T, Ermeza) 1.9%
Share of this specialty’s Medicare Part D prescriptions in 2024, including refills. Select a drug to see which of these clinicians prescribe it most, and where.
Hospitals where the most work
- Brigham and Women's Hospital Boston, MA 217 Medical Oncology at Brigham and Women's Hospital
- Massachusetts General Hospital Boston, MA 114 Medical Oncology at Massachusetts General Hospital
- Barnes Jewish Hospital Saint Louis, MO 105 Medical Oncology at Barnes Jewish Hospital
- Stanford Health Care Stanford, CA 91 Medical Oncology at Stanford Health Care
- Johns Hopkins Hospital, the Baltimore, MD 79 Medical Oncology at Johns Hopkins Hospital, the
- New York-Presbyterian Hospital New York, NY 70 Medical Oncology at New York-Presbyterian Hospital
- Ohio State University State Health System Columbus, OH 63 Medical Oncology at Ohio State University State Health System
- Barnes-Jewish West County Hospital Creve Coeur, MO 61 Medical Oncology at Barnes-Jewish West County Hospital
- Mayo Clinic Hospital Rochester Rochester, MN 60 Medical Oncology at Mayo Clinic Hospital Rochester
- Yale-New Haven Hospital New Haven, CT 57 Medical Oncology at Yale-New Haven Hospital
Clinicians who list the hospital in Medicare Care Compare. The number opens the list of who works there.
Schools they graduated from most
- Harvard Medical School 89
- Johns Hopkins University School of Medicine 51
- Perelman School of Med at The University of Pennsylvania 44
- Stanford University School of Medicine 43
- Albert Einstein College of Medicine of Yeshiva University 41
- Washington University School of Medicine 41
- Yale University School of Medicine 40
- Baylor College of Medicine 39
- New York University School of Medicine 37
- Columbia University College of Physicians and Surgeons 35
From Medicare Care Compare (Medicare-enrolled clinicians only).
Industry payments
Drug and device makers reported $42.0M in general payments to 3,414 clinicians in Medical Oncology in 2025. See who received the most
Source: CMS Open Payments, program year 2025. A payment is not evidence of wrongdoing.
Research in this field
U.S. researchers published 53,546 articles and reviews in oncology in 2024–2026.
Journals with the most U.S. papers
- Journal of Clinical Oncology Lippincott Williams & Wilkins 2,249
- Cancers Multidisciplinary Digital Publishing Institute 1,010
- Annals of Oncology Elsevier BV 978
- Cureus Cureus, Inc. 902
- Annals of Surgical Oncology Springer Science+Business Media 863
- Gynecologic Oncology Elsevier BV 737
- International Journal of Radiation Oncology*Biology*Physics Elsevier BV 673
- Laboratory Investigation Elsevier BV 652
- Neuro-Oncology Oxford University Press 615
- Transplantation and Cellular Therapy Elsevier BV 615
Most-cited recent papers
- Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (opens in a new tab) CA A Cancer Journal for Clinicians, 2024 · cited 30,549 times · free to read
- Cancer statistics, 2024 (opens in a new tab) CA A Cancer Journal for Clinicians, 2024 · cited 10,142 times · free to read
- Cancer statistics, 2025 (opens in a new tab) CA A Cancer Journal for Clinicians, 2025 · cited 3,609 times · free to read
- Global patterns and trends in breast cancer incidence and mortality across 185 countries (opens in a new tab) Nature Medicine, 2025 · cited 1,408 times
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study (opens in a new tab) The Lancet, 2024 · cited 974 times
- Breast cancer statistics 2024 (opens in a new tab) CA A Cancer Journal for Clinicians, 2024 · cited 905 times · free to read
- The Lancet Commission on prostate cancer: planning for the surge in cases (opens in a new tab) The Lancet, 2024 · cited 827 times · free to read
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma (opens in a new tab) New England Journal of Medicine, 2024 · cited 683 times · free to read
From OpenAlex, an open index of research papers. Papers with at least one author at a U.S. institution, classified by subject; the subject covers the whole field, so related specialties share these lists. Citation counts change daily.
Sources: CMS NPPES (counts, sex, credentials), Medicare Care Compare (schools, graduation years, hospitals, telehealth), CMS Medicare Physician & Other Practitioners (2023) and Part D Prescribers (2024), CMS Open Payments (2025), ACGME program requirements (training length), OpenAlex (research), U.S. Census Bureau ACS 2020–2024 (population).